The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...
Novo Nordisk's U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its ...
REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination ...
Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...
Zacks.com on MSN8d
NVO Stock Down 9% as CagriSema Misses Target in Second Obesity StudyNovo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second ...
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback